Aligos Therapeutics Inc (ALGS) Stock Price, Quote & News

Company Profile

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-12575...

Industry: Biotechnology

Sector: Healthcare

Phone: 800 466 6059

Website: www.aligos.com

Address:

One Corporate Drive, 2nd Floor, South San Francisco, United States

aletz Mar. 20 at 8:29 PM

$ALGS I'm really digging the recent price action, I've been able to snag quick 10% gains from swing trades a few times a week. Having conviction makes it easier to take positions since I don't mind buying more later anyway.

0 · Reply

HedgeUrHedge Mar. 20 at 7:41 PM

$ALGS please keep shorting the shares which are currently being created out of thin air so i can buy cheaper shares and report them to the SEC so they don't do shit and bail out institutions again. Price target is now $700/share and not selling anytime soon :)

1 · Reply

NasdaqKnight Mar. 20 at 11:38 AM

🚨 4 RATING UPDATES — DON'T SLEEP 🚨 👉If this is helpful to you, tap @NasdaqKnight $ADP — Guggenheim: BUY PT $270 vs current $208 AI fear? Overblown. Payroll needs deterministic outcomes — AI can't deliver. Moat: 12K tax jurisdictions, 8K banks integrated Trading near 52W low — accumulation zone? $AGO — PT Cut, But Look Deeper KBW: $108→$103, Outperform maintained Q4 was a BEAST: EPS beat by $0.78! Revenue +77.6%! Dividend hiked 11.8% PT cut = sentiment hit. Fundamentals? Rock solid. $AJG — PT Slashed Wells Fargo: $298→$273, Overweight stays Price: $351 → $209 (-40%) EPS beat, valuation already compressed Bottom fishing or falling knife? $ALGS — Jefferies: BUY PT $48 Fresh coverage, new eyes on the name

0 · Reply

SuperGreenToday Mar. 19 at 1:47 AM

$ALGS

0 · Reply

Quantumup Mar. 18 at 8:22 PM

Truist🏁 $IVA Buy; $13 $LLY $MDGL $NVO $ALGS VKTX ALT Truist said:::In our view, Inventiva has a differentiated approach in MASH with near-term Ph3 data (2H26) that we think could result in up to +100% upside from current levels. IVA's lead asset lanifibranor has a unique MOA/profile among MASH therapies in development that could make it an ideal choice for a niche group of MASH patients with diabetes. We believe its path to approval is de-risked given strong Ph2 data and FDA approval of drugs w/ similar MOAs. Our model shows that base case 3L use in MASH F2/F3 supports $2.3B WW peak adj. rev w/ add'l upside if lani is used preferentially MASH+diabetes.

0 · Reply

SuperGreenToday Mar. 17 at 11:17 PM

$ALGS

0 · Reply

Bwnuts Mar. 16 at 3:45 AM

$ALGS this thing really is on life support. Three options. 1) close up shop / bankruptcy. 2) pump pump pump it to raise cash and let investors short short short it. 3) sell it in desperation for pennies on the dollar .(avoid a 100% layoff). CMO probably saw the writing on the wall when he left. Options will most likely be worthless. When you see a long-term chart this bad, it’s probably best to stay away. Expensive lesson.

0 · Reply

OfficialStocktwitsUser Mar. 14 at 4:29 AM

$ALGS RSI: 60.68, MACD: -0.0989 Vol: 0.27, MA20: 7.04, MA50: 7.75 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

168_swingit Mar. 13 at 5:01 PM

$ALGS Very

0 · Reply

rational1 Mar. 12 at 12:44 PM

$SGMT $MDGL $GSK $IVA $ALGS

0 · Reply

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results

Feb 26, 2026, 8:00 AM EST - 23 days ago

Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026

Feb 23, 2026, 8:00 AM EST - 26 days ago

Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)

Jan 30, 2026, 8:00 AM EST - 7 weeks ago

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 21, 2026, 8:00 AM EST - 2 months ago

Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates

Dec 11, 2025, 8:00 AM EST - 3 months ago

Aligos Therapeutics Presents Positive Data at HEP-DART 2025

Nov 10, 2025, 8:00 AM EST - 4 months ago

Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025

Nov 6, 2025, 8:30 AM EST - 4 months ago

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results

Nov 4, 2025, 8:30 AM EST - 4 months ago

Aligos Therapeutics to Present at Upcoming Investor Conferences

Oct 30, 2025, 8:30 AM EDT - 5 months ago

Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025

Oct 16, 2025, 8:30 AM EDT - 5 months ago

Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184

Oct 14, 2025, 8:30 AM EDT - 5 months ago

Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference

Oct 7, 2025, 8:30 AM EDT - 5 months ago

Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025

Sep 3, 2025, 4:05 PM EDT - 7 months ago

Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting

Sep 2, 2025, 4:05 PM EDT - 7 months ago

Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 20, 2025, 8:30 AM EDT - 7 months ago

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs

Aug 13, 2025, 8:30 AM EDT - 7 months ago

Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection

Aug 6, 2025, 4:05 PM EDT - 8 months ago

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results

Jul 30, 2025, 4:05 PM EDT - 8 months ago

Aligos Therapeutics to Announce 2nd Quarter 2025 Financial Results on August 6, 2025

Jun 18, 2025, 8:00 AM EDT - 9 months ago

Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC)

May 29, 2025, 8:00 AM EDT - 10 months ago

Aligos Therapeutics to Present at the Jefferies Global Healthcare Conference

May 20, 2025, 8:00 AM EDT - 10 months ago

Aligos Therapeutics Appoints Laura Kavanaugh as Vice President, Head of Legal

May 8, 2025, 8:00 AM EDT - 11 months ago

Aligos Therapeutics Presents Positive Data at the EASL Congress 2025

May 6, 2025, 8:00 AM EDT - 11 months ago

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results

Apr 29, 2025, 8:30 AM EDT - 11 months ago

Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025

Apr 23, 2025, 4:05 PM EDT - 11 months ago

Aligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025

Mar 26, 2025, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Presents Positive Data at APASL 2025

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 8:00 AM EST - 1 year ago

Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025

Feb 12, 2025, 7:00 AM EST - 1 year ago

Aligos Therapeutics Announces $105 Million Private Placement Financing

Nov 19, 2024, 1:30 PM EST - 1 year ago

Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024

Nov 6, 2024, 4:05 PM EST - 1 year ago

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

Oct 1, 2024, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Appoints David Perry as Vice President of Business Development

Sep 30, 2024, 8:00 AM EDT - 1 year ago

Aligos Therapeutics to Present at Investor Conferences in October

Sep 19, 2024, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH

Sep 18, 2024, 5:00 PM EDT - 1 year ago

Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024

Aug 15, 2024, 9:00 AM EDT - 1 year ago

Aligos Therapeutics Announces Reverse Stock Split

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Aligos Therapeutics Strengthens Board with Two New Independent Directors

Jul 22, 2024, 9:00 AM EDT - 1 year ago

Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.

Jul 10, 2024, 8:00 AM EDT - 1 year ago

Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB

Jun 5, 2024, 2:30 AM EDT - 1 year ago

Aligos Therapeutics Presents Positive Data at the EASL Congress 2024

May 22, 2024, 4:05 PM EDT - 1 year ago

Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024

May 21, 2024, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH

Apr 30, 2024, 4:05 PM EDT - 2 years ago

Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024

Apr 25, 2024, 4:05 PM EDT - 2 years ago

Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study

Mar 27, 2024, 8:00 AM EDT - 2 years ago

Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies

Mar 12, 2024, 4:05 PM EDT - 2 years ago

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results

Mar 5, 2024, 4:05 PM EST - 2 years ago

Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024

Feb 26, 2024, 8:00 AM EST - 2 years ago

Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024

Feb 20, 2024, 8:00 AM EST - 2 years ago

Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024

aletz Mar. 20 at 8:29 PM

0 · Reply

HedgeUrHedge Mar. 20 at 7:41 PM

1 · Reply

NasdaqKnight Mar. 20 at 11:38 AM

0 · Reply

SuperGreenToday Mar. 19 at 1:47 AM

$ALGS

0 · Reply

Quantumup Mar. 18 at 8:22 PM

0 · Reply

SuperGreenToday Mar. 17 at 11:17 PM

$ALGS

0 · Reply

Bwnuts Mar. 16 at 3:45 AM

0 · Reply

OfficialStocktwitsUser Mar. 14 at 4:29 AM

0 · Reply

168_swingit Mar. 13 at 5:01 PM

$ALGS Very

0 · Reply

rational1 Mar. 12 at 12:44 PM

$SGMT $MDGL $GSK $IVA $ALGS

0 · Reply

Quantumup Mar. 11 at 8:27 PM

Oppenheimer reiterated $SGMT Outperform/$25, and said: SGMT reported 4Q25 results with $10.8M OpEx and $113.1M cash providing expected runway into 3Q27. $MDGL $IVA $NVO $ALGS VKTX RHHBY DRMA BFRI Oppenheimer added—We see key recent progress and several upcoming catalysts, including: 1) Ph1 PK study of the denifanstat plus resmetirom combination now supports a Ph2 trial in F4 MASH patients expected to initiate in 2H26; 2) partner Ascletis recently reported positive 52-week Ph3 results for denifanstat in moderate/severe acne demonstrating efficacy with favorable safety/tolerability supporting NDA filing acceptance by the Chinese NMPA, and we expect approval and launch in China ~early 2027; 3) Next-gen. FASN inhibitor TVB-3567 for acne Ph1 study data remains on track for 2026 followed by a Ph2 study pending regulatory alignment. We believe the differentiated MOA of FASN inhibition remains underappreciated while upcoming data readouts could drive upside.

0 · Reply

10PieceTeriyaki Mar. 8 at 2:16 PM

$ALGS

0 · Reply

10PieceTeriyaki Mar. 8 at 2:16 PM

$ALGS

0 · Reply

Bwnuts Mar. 6 at 3:29 AM

$ALGS keep your eye out for a candle like this here. This was 11/19/24. It would do nothing but go up for the next 60 days topping out at $46.80 in January. The low of this candle was $14 the high was $24. They blew out a ton of stops losses, grabbed liquidity and the artificial march up was game on. Watch out for that type of candle. That means something non-organic is happening.

1 · Reply

168_swingit Mar. 5 at 6:36 PM

$ALGS Start loading the boat!

1 · Reply

StocktwitsEarnings Mar. 5 at 6:30 PM

$ALGS Q4 '25 Earnings Results & Recap Aligos Therapeutics expects to incur losses for several years and its cash is projected to fund operations only into Q3 2026. This raises substantial doubt about Aligos Therapeutics' ability to continue as a going concern without additional funding.

0 · Reply

HedgeUrHedge Mar. 5 at 5:38 PM

$ALGS ignore the bs about 10-K. shorts keep moving the goal post. first they said they don't have a enough money and won't beat earning. now that they are better than what shorts expected they come up with another excuse lol. typical short and distort. we already knew they were running out of cash, but the burn rate is lower than what analysts were expecting.

2 · Reply

d_risk Mar. 5 at 3:45 PM

$ALGS - Aligos Therapeutics, Inc. - 10K - Updated Risk Factors ALGS flags heightened going-concern risk with auditor warning, runway only into Q3 2026 and dependence on new equity and collaborations, while facing early/mid-stage pipeline setbacks, pandemic vulnerability, multi-country trial delays, BIOSECURE Act/China trade and tariff exposure, and uncertainty around its HBV programs’ ultimate efficacy and approval. #Biotechnology #GoingConcernRisk #ClinicalTrialDelays #EquityFinancing #RegulatoryUncertainty 🟢 Added 🟠 Removed https://d-risk.ai/ALGS/10-K/2026-03-05

0 · Reply

HedgeUrHedge Mar. 5 at 1:52 AM

$ALGS analysts will obviously short on the financials. hope they understand exaggerating financial results while downplaying actual data results is not actually analyzing a stock its feeding only one side of the story and tipping the scales in their favor and ignoring what they currently have compared to current drugs in similar situations. its a false narrative.

0 · Reply

Buyhighsellatlow Mar. 4 at 7:00 PM

$ALGS Analysts are expecting a loss per share (EPS) around about –$2.09 for the quarter. In the prior quarter, $ALGS reported a loss of –$3.04 per share, which missed expectations (analysts had been looking for about –$2.09). Total cash + short-term investments: ~$99.1 million (combined) as of Sep 30 2025. Management has stated the current runway should fund planned operations into the third quarter of 2026, though the filing also includes a “going concern” note indicating they may still need additional financing.

0 · Reply

Bwnuts Mar. 3 at 3:06 PM

$ALGS is there still a pulse?

0 · Reply

Bwnuts Feb. 26 at 3:15 PM

$ALGS wow this appears to be on life support. Webull showing zero volume 30 minutes in. Add to that, some major money hit the abort button last week. There’s a reason the chart has been down and to the right since IPO. anyone heard from the CEO?

2 · Reply

Market Cap	43.01M
Revenue (ttm)	2.19M
Net Income (ttm)	-24.19M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,104.57%
Debt to Equity Ratio	0.00

Volume	58,200
Avg Vol	56,358
Day's Range	N/A - N/A
Shares Out	6.19M
Stochastic %K	0%
Beta	2.67
Analysts	Strong Sell
Price Target	$70.25